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Abstract 
Background: Pooled data from two large registries, Cubicin® Outcomes Registry and Experience (CORE; USA) and 
European Cubicin® Outcomes Registry and Experience (EU‑CORE; Europe, Latin America, and Asia), were analyzed to 
determine the characteristics and clinical outcomes of daptomycin therapy in patients with Gram‑positive infections 
across wide geographical regions.
Methods: Patients receiving at least one dose of daptomycin between 2004 and 2012 for the treatment of Gram‑
positive infections were included. Clinical success was defined as an outcome of ‘cured’ or ‘improved’. Post‑treatment 
follow‑up data were collected for a subset of patients (CORE: osteomyelitis and orthopedic foreign body device infec‑
tion; EU‑CORE: endocarditis, intracardiac/intravascular device infection, osteomyelitis, and orthopedic device infec‑
tion). Safety was assessed for up to 30 days after daptomycin treatment.
Results: In 11,557 patients (CORE, 5482; EU‑CORE, 6075) treated with daptomycin (median age, 62 [range, 1–103] 
years), the most frequent underlying conditions were cardiovascular disease (54.7 %) and diabetes mellitus (28.0 %). 
The most commonly treated primary infections were complicated skin and soft tissue infection (cSSTI; 31.2 %) and 
bacteremia (21.8 %). The overall clinical success rate was 77.2 % (uncomplicated SSTI, 88.3 %; cSSTI, 81.0 %; osteomy‑
elitis, 77.7 %; foreign body/prosthetic infection (FBPI), 75.9 %; endocarditis, 75.4 %; and bacteremia, 69.5 %). The clinical 
success rate was 79.1 % in patients with Staphylococcus aureus infections (MRSA, 78.1 %). An increasing trend of high‑
dose daptomycin (>6 mg/kg/day) prescribing pattern was observed over time. Clinical success rates were higher with 
high‑dose daptomycin treatment for endocarditis and FBPI. Adverse events (AEs) and serious AEs possibly related to 
daptomycin therapy were reported in 628 (5.4 %) and 133 (1.2 %) patients, respectively.
Conclusions: The real‑world data showed that daptomycin was effective and safe in the treatment of various Gram‑
positive infections, including those caused by resistant pathogens, across wide geographical regions.
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Background
Resistant Gram-positive pathogens such as methicil-
lin-resistant Staphylococcus aureus (MRSA) and van-
comycin-resistant enterococci (VRE) are associated 
with increased morbidity, mortality, and healthcare 
expenditures in hospitalized patients [1, 2]. Vancomycin 
is known to be an active agent for the treatment of Gram-
positive infections, but there are concerns regarding its 
declining efficacy, potentially due to the “minimum inhib-
itory concentration creep” in MRSA [1, 3]. Therapeutic 
options such as clindamycin, co-trimoxazole, fluoroqui-
nolones, minocycline, or the addition of rifampin may be 
useful, however, their use is limited to patients without 
life-threatening infections [4, 5]. Moreover, resistance 
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to linezolid has been reported and its prolonged expo-
sure can lead to myelosuppression [6, 7]. Other antibiot-
ics with MRSA activity such as ceftaroline, ceftobiprole, 
telavancin, and tigecycline represent alternatives for the 
treatment of infections caused by drug-resistant Gram-
positive pathogens [8]. However, there are some reports 
of safety issues associated with these antibiotics; hema-
tological disorders and rash with ceftaroline, gastro-
intestinal upset with ceftobiprole, nephrotoxicity with 
telavancin, and pancreatitis with tigecycline [9–12].
Treatment choices are increasing for Gram-positive 
infections, including those caused by resistant patho-
gens. Various agents have either been recently approved 
(e.g. tedizolid, oritavancin) [8] or are under development, 
reflecting the need for “niche” antibiotics, particularly for 
difficult-to-treat infections [4, 13, 14].
Daptomycin is a cyclic lipopeptide with rapid bacteri-
cidal activity against a wide range of Gram-positive path-
ogens such as methicillin-susceptible S. aureus (MSSA), 
MRSA, and VRE [15, 16]. Daptomycin is approved in 
adult patients for the treatment of complicated skin and 
soft tissue infection (cSSTI; 4  mg/kg/day), right-sided 
infective endocarditis (RIE) due to S. aureus, and bacte-
remia associated with cSSTI or RIE (6  mg/kg/day) [17, 
18]. However, high-dose (>6  mg/kg/day) daptomycin is 
often recommended for difficult-to-treat infections [14, 
19–22]. Several study reports showed that high-dose 
daptomycin is increasingly used in patients with various 
deep seated infections and in those failing treatment with 
other antibiotics [23–26]. In addition to the approved 
indications, daptomycin has shown to be effective in the 
treatment of other infections, such as left-sided infective 
endocarditis (LIE), osteomyelitis, and orthopedic device 
infections [27–29]. Randomized controlled trials have 
shown a favorable safety and efficacy profile of daptomy-
cin in patients with S. aureus bacteremia, endocarditis, 
and osteomyelitis/orthopedic device infections [30–32].
The Cubicin® Outcomes Registry and Experience 
(CORE) and the European Cubicin® Outcomes Registry 
and Experience (EU-CORE), both multicenter, retrospec-
tive, non-interventional registries, were conducted to 
collect real-world data on the characteristics and clini-
cal outcomes of patients receiving daptomycin [33, 34]. 
CORE included data from approximately 164 sites in the 
United States of America (USA) [35–37], whereas EU-
CORE comprised data from 310 sites across 18 countries 
in Europe (12), Latin America (5), and Asia (1). Various 
independent reports on the results from CORE (2004–
2009) and EU-CORE (2006–2012) have been published 
[33–36, 38]. The results of CORE and EU-CORE showed 
that daptomycin is also used for treating infections other 
than those approved [35, 39]. Combining data from two 
real-world registries conducted in different regions may 
help in understanding the trend of prescribing patterns 
and duration of treatment versus effectiveness and safety 
in a large number of patients treated with daptomycin 
between 2004 and 2012.
Methods
Patients and data collection
The protocols were approved by the health authority 
and the Institutional Review Board (IRB) or Ethics Com-
mittee (EC) of each participating country. The method-
ologies have been published previously [36, 40]. Written 
informed consent was obtained from patients according 
to the requirements of the IRB or EC and/or the local 
data privacy regulations. Patients who had received at 
least one dose of daptomycin between January 2004 
and April 2012 for treatment of Gram-positive bacterial 
infections were included. Patients should have been fol-
lowed up for 30  days after treatment. Patients who had 
received daptomycin as part of a controlled clinical trial 
were not eligible. In CORE, patients with osteomyelitis 
or orthopedic foreign body device infection (enrolled 
between 2007 and 2008) were evaluated at the end of 
daptomycin treatment; those with at least one post-
treatment follow-up assessment were also included in 
the follow-up data collection up to 2009. In EU-CORE, 
patients with endocarditis, intracardiac/intravascular 
device infection, osteomyelitis, or orthopedic device 
infection were followed for up to 2  years from 2012 to 
2014. In both registries, the overlapping data collection 
period was from 2007 to 2009. Demographic, antibiotic, 
microbiologic, and clinical data were recorded retrospec-
tively using standardized case report forms as per the 
protocols. This analysis extracted data from all patients 
who received daptomycin from 2004 to 2012 (CORE, 
2004–2009; EU-CORE, 2006–2012).
Definitions
Clinical outcomes were assessed by investigators at the 
end of daptomycin treatment based on the following pro-
tocol-defined criteria: cured, clinical signs and symptoms 
resolved, no additional antibiotic therapy was necessary, 
or infection cleared with a negative culture reported; 
improved, partial resolution of clinical signs and symp-
toms and/or additional antibiotic therapy was warranted; 
failed, inadequate response to daptomycin therapy, 
worsening or new/recurrent signs and symptoms, need 
for a change in antibiotic therapy, or a positive culture 
reported at the end of the therapy; and non-evaluable, 
unable to determine response due to insufficient infor-
mation. Clinical success was defined as an outcome of 
‘cured’ or ‘improved’. Time to improvement was recorded. 
The reasons for discontinuation of daptomycin therapy 
and details of other antibiotics prescribed concomitantly 
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or following daptomycin were also recorded. Among all 
registry-enrolled patients, the safety population com-
prised patients for whom any safety parameters were 
assessed, and the efficacy population comprised patients 
for whom clinical outcomes were assessed. All adverse 
events (AEs) were reported, regardless of their relation-
ship to daptomycin; the severity of these AEs was deter-
mined by the investigators.
Statistical analysis
Statistical analysis was performed using SAS version 9.3 
(SAS Institute Inc., Cary, NC, USA). Due to the nature of 
the two observational uncontrolled registry trials, infer-
ential analyses were not conducted and no formal statis-
tical methodology, except simple descriptive statistics, 
was used. All analyses were considered to be explana-
tory. Numerical variables were summarized as arithmetic 
mean, standard deviation, median, minimum, first quar-
tile, third quartile, and maximum for the continuous vari-
ables, whereas the categorical variables were summarized 
according to absolute and relative frequencies.
Logistic regression analysis was performed to assess 
risk factors for CPK elevation, with CPK elevation (yes/
no) as response variable and the following variables as 
covariates: age, use of statin therapy, history of renal dis-
ease or diabetes mellitus, significant underlying disease, 
infection type, initial dose level, surgical procedure, con-
comitant use of antibiotics, creatinine clearance (CrCl), 
and baseline CPK.
Results
Patient demographics and clinical characteristics
A total of 11,557 patients (CORE, 5482; EU-CORE, 6075) 
treated with daptomycin were included in this analysis. 
Baseline patient demographic and clinical characteristics 
by overall pooled data and individual studies during the 
overlapping period from 2007 to 2009, are summarized 
in Table 1. The median age of the patients was 62 (range, 
1–103) years, with 38.4 % aged ≥65 years, and a majority 
(88.7 %) having significant underlying diseases. The most 
common underlying conditions were cardiovascular dis-
ease (54.7 %) and diabetes mellitus (28.0 %), followed by 
malignancy (16.7 %) and renal disease (16.6 %). Daptomy-
cin was used to treat a wide range of primary infections 
(Table 2). The commonly treated primary infections were 
cSSTI (31.2  %), bacteremia (21.8  %), foreign body/pros-
thetic infection (FBPI; 8.5 %), osteomyelitis (8.6 %), and 
endocarditis (6.9 %; including 3.9 % with LIE). The most 
common secondary infections were bacteremia (3.8  %), 
cSSTI (2.6  %), osteomyelitis (1.7  %), and endocarditis 
(1.2 %). Overall, 14.5 % of patients had renal impairment 
(CrCl  <30  mL/min) and 1095 (9.5  %) patients were on 
dialysis at the time of initiation of daptomycin therapy.
Microbiology
Culture results were available for a total of 9664 (83.6 %) 
patients, of whom 7912 (81.9  %) had positive culture 
results and 1752 (18.1  %) had negative culture results 
(Table  2). The most frequently isolated pathogens in 
patients with positive culture results were S. aureus 
(46.4 %, including 28.6 % MRSA and 14.0 % MSSA), coag-
ulase-negative staphylococci (CoNS; 21.4 %), and entero-
cocci (17.4 %; VRE, 7.3 %).
Previous and concomitant therapies
The majority of patients (n  =  8221; 71.1  %) received 
prior antibiotic therapy, most commonly glycopeptides 
(34.3 %; vancomycin, 30.6 %; teicoplanin, 4.2 %), penicil-
lins (19.5 %), cephalosporins (15.6 %), and fluoroquinolo-
nes (13.9  %). The most common reasons for switching 
to daptomycin included failure of prior antibiotic ther-
apy (28.0  %), resistant or non-susceptible Gram-posi-
tive organism (10.7  %), and narrow antibiotic spectrum 
(10.0 %). Daptomycin was used concomitantly with other 
antibiotics in 6631 (57.4 %) patients who received treat-
ment in an inpatient setting; the frequently administered 
concomitant antibiotics were carbapenems (17.6 %), pen-
icillins (12.1 %), fluoroquinolones (11.5 %), and cephalo-
sporins (10.0 %).
Table 1 Baseline patient demographic and clinical charac-
teristics
Data are presented as n (%), unless indicated otherwise
a Data are from three overlapping periods: 2007–2009
b Data missing for 5 patients
c Data missing for 19 patients











Male 6587 (57.0) 1454 (51.4) 2150 (64.5)
Ageb (years), median 
(range)
62.0 (1–103) 56.5 (4–99) 63.0 (1–103)
 <65 years 7111 (61.5) 1945 (68.8) 1758 (52.7)
 ≥65 years 4441 (38.4) 882 (31.2) 1572 (47.2)
 ≥75 years 1732 (15.0) 265 (9.4) 734 (22.0)
Body weight (kg), median 
(range)
78.0 (6–275) 81.9 (15–259) 75.0 (6–200)
Race, Caucasian 7191 (62.2) 1967 (69.6) 3058 (91.7)
Setting prior to daptomycin therapyc
 Hospital 7278 (63.0) 1359 (49.3) 2558 (76.7)
 Nursing home/extended 
care
431 (3.7) 152 (5.4) 102 (3.1)
 Community 3772 (32.6) 1275 (45.1) 637 (19.1)
 Other 57 (0.5) 5 (0.2) 24 (0.7)
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Daptomycin prescribing patterns
The most commonly prescribed dose of daptomycin was 
6 mg/kg/day (n = 4968; 43.0 %), followed by 4 mg/kg/day 
(n = 3469; 30.0 %). A similar daptomycin prescribing pat-
tern was noted in the overlapping period of CORE (6 mg/
kg/day [48.5  %], followed by 4  mg/kg/day [26.6  %]) and 
EU-CORE (6 mg/kg/day [45.5 %], followed by 4 mg/kg/
day [29.9 %]). In particular, 54.2 % of patients with bacte-
remia and 42.0 % patients with cSSTI were treated with 
daptomycin 6  mg/kg/day and 4  mg/kg/day, respectively. 
A total of 1564 (13.5 %) patients received high-dose dap-
tomycin (>6 mg/kg/day). A trend toward use of higher 
doses (>6  mg/kg/day) over time was observed for most 
of the infections, particularly in patients with bacteremia, 
osteomyelitis, and FBPI (Fig. 1).
Overall, the median duration of treatment with dapto-
mycin was 12.0 (range, 1–370) days; 8.0 (range, 1–246) 
days in the inpatient setting and 16.0 (range, 1–358) days 
in the outpatient setting. The mean duration of dapto-
mycin treatment according to inpatient/outpatient treat-
ment settings over time (years) is shown in Fig.  2. The 
duration of treatment was lower in inpatients compared 
with outpatients. Among the key primary infections, 
the median inpatient treatment duration was longest for 
endocarditis at 16.0 (range, 1–112) days and shortest for 
uncomplicated SSTI (uSSTI) at 6.0 (range, 1–56) days. 
The mean durations of daptomycin treatment by primary 
infection over time are shown in Fig. 3. The duration of 
treatment was higher for endocarditis, FBPI, and osteo-
myelitis as compared with uSSTI, cSSTI, and bacteremia. 
An increasing trend was observed in mean duration of 
treatment for osteomyelitis, FBPI, and endocarditis over 
time.
A total of 6471 (56.0  %) patients completed the dap-
tomycin treatment; however, 23.4  % switched therapy 
(e.g., stepped-down to oral antibiotic therapy). Discon-
tinuation of daptomycin therapy due to AEs and treat-
ment failure was reported in 4.6 and 3.3  % of patients, 
respectively.
Clinical outcomes
An overall clinical success rate of 77.2  % was reported 
with daptomycin therapy. The clinical success rates 
ranged from 69.5  % for bacteremia to 88.3  % for uSSTI 
(Fig. 4). The clinical success rates during the overlapping 
period (2007–2009) were similar overall and for the dif-
ferent primary infections. The success rates in patients 
with resistant pathogens such as MRSA and VRE were 
78.1 and 68.8 %, respectively (Fig. 5).
The clinical success rate was slightly higher (80.3  %) 
when daptomycin was used as a first-line than that 
Table 2 Primary infections and pathogens
CoNS coagulase-negative staphylococci
a Data are from three overlapping periods: 2007–2009
b Includes septic arthritis, urinary tract infections/pyelonephritis, central 
nervous system infections, metastatic abscess, antibiotic prophylaxis (surgical 
and non-surgical), neutropenic fever, necrotizing fasciitis, necrotizing infections, 
unknown or not otherwise specified infections, and data missing
c Percentage is calculated based on positive culture results
d Includes Clostridium difficile, Clostridium perfringens, Clostridium species, 
Corynebacterium species, Staphylococcus species coagulase not specified, Gram-
positive and Gram-negative bacilli and cocci, Leuconostoc species, Peptococcus 
species, Peptostreptococcus species, fungi/yeast, viruses, and organisms with 
invalid/ambiguous pathogen code











Complicated skin and soft 
tissue infection
3607 (31.2) 803 (28.4) 1092 (32.8)
Bacteremia 2522 (21.8) 642 (22.7) 741 (22.2)
Endocarditis 798 (6.9) 103 (3.6) 338 (10.1)
Foreign body/prosthetic 
infection
988 (8.5) 217 (7.7) 294 (8.8)
Osteomyelitis (non‑pros‑
thetic and prosthetic 
device‑related)
994 (8.6) 281 (9.9) 193 (5.8)
Uncomplicated skin and 
soft tissue infection
1510 (13.1) 475 (16.8) 334 (10.0)
Otherb 1138 (9.8) 306 (10.8) 341 (10.2)











Staphylococcus aureus 3673 (46.4) 925 (46.2) 931 (41.6)
 Methicillin‑susceptible 1104 (14.0) 208 (10.4) 356 (15.9)
 Methicillin‑resistant 2261 (28.6) 621 (31.0) 509 (22.7)
 Susceptibility unknown 308 (3.9) 96 (4.8) 66 (2.9)
CoNS 1690 (21.4) 276 (13.8) 677 (30.2)
 Staphylococcus epider-
midis
850 (10.7) 103 (5.1) 390 (17.4)
 Staphylococcus spp.–
coagulase negative
840 (10.6) 173 (8.6) 287 (12.8)
Enterococci 1380 (17.4) 495 (24.7) 255 (11.4)
 Vancomycin‑resistant 576 (7.2) 284 (14.2) 36 (1.0)
  Enterococcus faecalis 492 (6.2) 134 (6.7) 125 (5.6)
   Vancomycin‑resistant 83 (1.0) 37 (0.5) 10 (0.3)
  Enterococcus faecium 684 (8.6) 277 (13.8) 110 (4.9)
   Vancomycin‑resistant 493 (6.2) 247 (12.3) 26 (0.8)
  Enterococcus spp. 204 (2.6) 84 (4.2) 20 (0.9)
Streptococci 326 (4.1) 71 (3.5) 98 (4.4)
Otherd 843 (10.7) 235 (11.7) 279 (12.5)
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when used as a second-line therapy (75.9 %). For infec-
tions associated with MRSA as the primary pathogen, 
the clinical success rate with first-line daptomycin 
treatment (n = 841) was 83.7 % compared with 76.3 % 
with second-line daptomycin treatment (n  =  2819). 
Clinical success rates tended to be higher with increas-
ing daptomycin doses for endocarditis and FBPI 
(Fig. 6).
The patients who received daptomycin as monotherapy 
reported higher (82.7 %) clinical success rates than those 
who received concomitant antibiotic therapy (74.3 %).
Safety
Daptomycin was generally well tolerated. AEs, regard-
less of their relationship to daptomycin treatment, were 
reported in 1879 (16.3 %) patients, and serious AEs (SAEs) 
were reported in 1050 (9.1  %) patients. Increased blood 
creatine phosphokinase (CPK; 1.9  %), multi-organ fail-
ure (1.0 %), and sepsis (1.0 %) were the most commonly 
reported AEs regardless of relationship to daptomycin 
treatment, and the most common SAEs were multi-organ 
failure (1.0  %), sepsis (1.0  %), and septic shock (0.7  %). 
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Fig. 2 Mean durations of daptomycin treatment according to inpatient and outpatient treatment settings over time (2005–2012)
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were reported in 628 (5.4  %) and 133 (1.2  %) patients, 
respectively. Elevated blood CPK levels in 175 (1.5  %) 
patients, myalgia in 21 (0.2 %) patients, rhabdomyolysis in 
12 (0.1 %) patients, and both myopathy and eosinophilic 
pneumonia in 4 (0.03  %) patients each were reported as 
AEs possibly related to daptomycin treatment.
Blood CPK levels at baseline were measured in 4206 














































Fig. 3 Mean durations of daptomycin treatment by primary infection over time (2005–2012). cSSTI complicated skin and soft tissue infection, FBPI 
foreign body/prosthetic infection










































Fig. 4 Clinical outcomes by primary infection. cSSTI complicated skin and soft tissue infection, FBPI foreign body/prosthetic infection, uSSTI uncom‑
plicated skin and soft tissue infection
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83.3  %) had CPK levels  ≤1  ×  upper limit of nor-
mal (ULN), 72 (1.7  %) had levels  >5–10  ×  ULN, and 
115 (2.7  %) had levels  >10  ×  ULN. Blood CPK levels 
during daptomycin therapy were measured in 5024 
(43.5  %) patients; of those, 3794 (75.5  %) had CPK lev-
els ≤1 × ULN, 126 (2.5 %) had levels >5–10 × ULN, and 
166 (3.3 %) had levels >10 × ULN.
Results of the logistic regression analysis to assess risk 
factors for CPK elevation showed that factors such as age, 
initial daptomycin dose and CrCl were not statistically 
significant at 5 % level of significance; however, surgical 
intervention and concomitant antibiotic therapy were 
found to be statistically significant at 5 % level of signifi-
























































Fig. 5 Clinical outcomes by primary pathogen. CoNS coagulase‑negative staphylococci, MRSA methicillin‑resistant S. aureus, MSSA methicillin‑






































6 mg/kg/day >6 to <8 mg/kg/day 8 mg/kg/day
Fig. 6 Clinical success rates for primary infection by daptomycin dose. cSSTI complicated skin and soft tissue infection, FBPI foreign body/prosthetic 
infection
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a shift of CPK elevation from  ≤10  ×  ULN at baseline 
to >10 × ULN. AEs leading to study drug discontinuation 
occurred in 519 (4.5 %) patients, most frequently due to 
infections and infestations (1.0 %) including sepsis (0.3 %) 
and septic shock (0.3 %). A total of 674 (5.8 %) patients 
died during the daptomycin treatment; the most frequent 
causes of death were sepsis (0.9  %) and septic shock 
(0.7 %).
Discussion
The CORE and EU-CORE pooled data analysis reflects 
the clinical experience with daptomycin use in a real-
world setting. The results suggest that daptomycin is 
widely used to treat various infections caused by Gram-
positive bacteria, including resistant strains (MRSA, 
CoNS, and VRE), in a complex patient population with 
multiple co-morbidities across the USA, Europe, Latin 
America, and Asia. Daptomycin demonstrated good 
safety and effectiveness outcomes, when used as sec-
ond- or first-line therapy. Daptomycin was used to treat 
the approved indications (cSSTI, bacteremia, and RIE). 
In addition, patients with LIE, osteomyelitis, prosthetic 
joint infections, neutropenic fever, sepsis of unknown 
origin, and surgical site infections caused by Gram-posi-
tive pathogens were also treated, which reflects an unmet 
medical need of approved treatment options for these 
conditions. Several reports have suggested that dapto-
mycin is effective and has an overall good safety profile 
in various clinical conditions such as SSTI, bacteremia, 
osteomyelitis and endocarditis in different geographical 
regions [15, 29, 41–43]. Rege et  al. have reported good 
tolerability and high clinical success rates with daptomy-
cin when administered for  >14  days, in a patient popu-
lation from the USA [34]. Similarly, the results from an 
8-year clinical experience with daptomycin showed 
favorable safety and effectiveness profiles with lower 
overall clinical failure rates in Europe, Latin America, and 
Asia [33, 40, 43]. These results complement the previ-
ously published data from randomized clinical trials [31, 
32]. Treatment with daptomycin in the real-world setting 
showed high clinical success rates across a range of path-
ogens, both for labeled (cSSTI, bacteremia, and RIE), and 
non-labeled (osteomyelitis, FBPI, and LIE) infections. 
High success rates with daptomycin treatment were 
observed irrespective of first-line or second-line use. In 
patients with MRSA infections, the clinical success rates 
0.0 0.5 1.0 1.5 2.0
Surgery










>80 vs <30 mL/min 0.941 (0.699, 1.267)
CrCl
30 - <50 vs <30 mL/min 1.191 (0.838, 1.694)
Age




8 vs 6 mg/kg/day
Initial dose
>6 - <8 vs 6 mg/kg/day
1.123 (0.841, 1.498)
1.112 (0.786, 1.574)
Fig. 7 Logistic regression analysis of CPK elevation versus risk factors. Data are presented as odds ratio and 95 % confidence interval. CrCl creatinine 
clearance
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were numerically higher with first-line (83.7  %) com-
pared with second-line (76.3  %) daptomycin treatment. 
Increased use of first-line daptomycin treatment for 
suspected and confirmed resistant pathogens, such as 
MRSA, reflects increasing awareness of daptomycin use 
for resistant pathogens and the limitations of available 
treatment options [31, 32, 44]. This pooled analysis rein-
forces the data from the previously published real-world 
reports (CORE and EU-CORE) [33, 35].
Considering the linear pharmacokinetics and dose-
dependent bactericidal activity of daptomycin [45], high 
dose (>6  mg/kg/day) is sometimes recommended to 
minimize the risk of resistance development in patients 
with difficult-to-treat infections including those caused 
by resistant pathogens (MRSA and VRE) [45–47]. Dap-
tomycin has a long half-life of 8  h, and demonstrates a 
prolonged post-antibiotic effect of up to 6.8 h. It is highly 
bound to serum proteins (90  %) and is distributed pri-
marily in the extracellular fluid. It effectively penetrates 
bone and inflamed soft tissues and, therefore, is effica-
cious in the treatment of deep tissue infections [18, 48].
A number of national and international guidelines 
recommend high-dose daptomycin (>6  mg/kg/day) as 
a possible therapeutic alternative for difficult-to-treat 
infections [20, 21, 49, 50]. In combination with other 
antibiotics, daptomycin (10  mg/kg/day) is also recom-
mended for persistent MRSA bacteremia and vancomy-
cin treatment failures [19, 20, 49, 51].
A study including 70 patients with IE receiving high-
dose daptomycin (≥8  mg/kg/day) has shown successful 
clinical outcomes in all patients without any reports of 
discontinuation due to toxicity or AEs [52]. In a larger 
study of 250 patients with complicated Gram-positive 
infections, high-dose daptomycin (8  mg/kg/day) was 
reported to be effective and have a favorable safety pro-
file [52]. Furthermore, various studies demonstrated that 
high-dose daptomycin is effective and well tolerated in 
the treatment of difficult-to-treat infections such as LIE, 
mediastinitis after cardiac surgery, and osteomyelitis [7, 
52]. The results from the current analysis showed a trend 
toward the use of higher doses (>6 mg/kg/day) over time 
with high success rates for endocarditis and FBPI, which 
is also supported by previously published literature [7, 49, 
52].
It is well recognized that daptomycin treatment is associ-
ated with blood CPK elevation, however, no significant cor-
relation was reported between daptomycin dose and blood 
CPK elevation [14, 53, 54]. In the present analysis, a small 
proportion of patients experienced elevation in blood CPK 
levels; however, this was not always associated with adverse 
musculoskeletal effects. There was no correlation observed 
between blood CPK elevation and factors such as age, ini-
tial daptomycin dose, or CrCl. Furthermore, no new or 
unexpected safety findings were observed in this analysis. 
These safety results are consistent with earlier published 
real-world reports from the USA and Europe [34, 41, 55].
The registries have inherent limitations, such as the 
retrospective nature of the data collection and non-
comparative, non-blinded, and non-randomized design. 
However, the registries allow the inclusion of diverse 
infections and the use of concomitant antibiotics, includ-
ing broad-spectrum antibiotics. Therefore, the results 
mimic real-world clinical experience with daptomycin 
and expand the evidence derived from clinical trials.
The present analysis re-affirms the real-world safety 
and effectiveness of daptomycin across wide geographi-
cal regions including the USA and Europe. The data sug-
gest that daptomycin is effective and well tolerated for 
the management of difficult-to-treat infections caused 
by various Gram-positive pathogens, including those 
caused by resistant species (MSSA, MRSA, CoNS, and 
VRE). Moreover, a trend of increased use of high-dose 
daptomycin was noted over time, specifically in patients 
with endocarditis, osteomyelitis, and prosthetic joint 
infections.
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